Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
País como assunto
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Acta Derm Venereol ; 103: adv14153, 2023 Oct 06.
Artigo em Inglês | MEDLINE | ID: mdl-37800349

RESUMO

The efficacy and safety of baricitinib for treatment of atopic dermatitis have been demonstrated in clinical trials; however, very few real-life studies have been published to date. The Observatory of Chronic Inflammatory Skin Diseases (OMCCI) registry was initiated to prospectively determine the long-term impairment caused by chronic inflammatory dermatoses on patients' lives. The study included 88 patients starting baricitinib for treatment of atopic dermatitis. Clinical evaluation and patient-reported outcomes were recorded at baseline and after 6 and 12 months. After 6 months and 1 year of follow-up, 65 and 47 patients, respectively, were still being treated with baricitinib. Treatment failure was the main reason for discontinuation. Only 1 patient stopped baricitinib because of a side-effect. After 1 year of follow-up, the mean Eczema Area and Severity Index score decreased significantly from 20.7 to 6.4; the percentage of patients with severe atopic dermatitis decreased from 42.9% to 6.5% and a significant improvement in most patient-reported outcomes was noted. There was no difference in terms of efficacy whether or not patients were previously treated with dupilumab. The results remained stable after 6 and 12 months of treatment, which suggests a sustained efficacy of the treatment in patients who initially responded well.


Assuntos
Azetidinas , Dermatite Atópica , Humanos , Dermatite Atópica/diagnóstico , Dermatite Atópica/tratamento farmacológico , Qualidade de Vida , Azetidinas/efeitos adversos , Sistema de Registros , Resultado do Tratamento , Índice de Gravidade de Doença , Método Duplo-Cego
2.
Emerg Infect Dis ; 25(12): 2197-2204, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31742503

RESUMO

Zoonotic transmission of parapoxvirus from animals to humans has been reported; clinical manifestations are skin lesions on the fingers and hands after contact with infected animals. We report a human infection clinically suspected as being ecthyma contagiosum. The patient, a 65-year-old woman, had 3 nodules on her hands. She reported contact with a sheep during the Aïd-el-Fitr festival in France during 2017. We isolated the parapoxvirus orf virus from these nodules by using a nonconventional cell and sequenced the orf genome. We identified a novel orf virus genome and compared it with genomes of other orf viruses. More research is needed on the genus Parapoxvirus to understand worldwide distribution of and infection by orf virus, especially transmission between goats and sheep.


Assuntos
Ectima Contagioso/diagnóstico , Ectima Contagioso/virologia , Genoma Viral , Vírus do Orf/genética , Biópsia , DNA Viral , Ectima Contagioso/epidemiologia , Ectima Contagioso/história , França/epidemiologia , História do Século XXI , Humanos , Vírus do Orf/classificação , Vírus do Orf/isolamento & purificação , Vírus do Orf/ultraestrutura , Filogenia , Reação em Cadeia da Polimerase , Vigilância da População , Sequenciamento Completo do Genoma
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa